Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
ADCT
$4.39
$
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Next Earnings
2026-02-25
Beta
1.954
Average Volume
Market Cap
Last Dividend
CIK
0001771910
ISIN
CH0499880968
CUSIP
H0036K147
CEO
Ameet Mallik
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
263
IPO Date
2020-05-18
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| ADC Therapeutics to Participate in March Investor Conferences | LAUSANNE, Switzerland, Feb. 24, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in upcoming investor conferences in March: TD Cowen 46th Annual Health Care ConferenceDate: Tuesday, March 3, 2026Presentation Time: 11:50 a.m. ESTFormat: Corporate presentationSpeaker: Ameet Mallik, Chief Executive OfficerLocation: Boston, MATo register for the webcast, click here. | PRNewsWire | 2026-02-24 07:15:00 |
| ADC Therapeutics Announces Amended HealthCare Royalty Financing Agreement | LAUSANNE, Switzerland, Feb. 23, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it has entered into an amendment to its royalty purchase agreement with entities managed by HealthCare Royalty. Based on confidence in the long-term outlook for ZYNLONTA®, ADC Therapeutics negotiated mutually beneficial updated terms with HealthCare Royalty, offering greater strategic flexibility to the Company. | PRNewsWire | 2026-02-23 07:15:00 |
| Analysts Set ADC Therapeutics SA (NYSE:ADCT) Price Target at $7.50 | ADC Therapeutics SA (NYSE: ADCT - Get Free Report) has earned an average recommendation of "Moderate Buy" from the six research firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12 month target price | Defense World | 2026-02-10 01:46:44 |
| ADC Therapeutics Makes Grants to New Employees Under Inducement Plan | LAUSANNE, Switzerland, Feb. 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 308,000 of the Company's common shares to seven new employees on February 2, 2026 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment. | PRNewsWire | 2026-02-02 16:05:00 |
| Has ADC Therapeutics (ADCT) Outpaced Other Medical Stocks This Year? | Here is how ADC Therapeutics SA (ADCT) and Assertio (ASRT) have performed compared to their sector so far this year. | Zacks Investment Research | 2026-01-30 10:40:47 |
| $170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium | /PRNewswire/ -- The oncology sector is undergoing a massive capital rotation driven by over 50 FDA approvals in 2025, with 20 arriving in Q4 alone[1]. This | PRNewsWire | 2026-01-30 10:36:00 |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT | NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC Therapeutics" or the "Company") (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. | PRNewsWire | 2026-01-22 10:00:00 |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT | NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC Therapeutics” or the “Company”) (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. | GlobeNewsWire | 2026-01-20 16:37:00 |
| ADC Therapeutics SA (ADCT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript | ADC Therapeutics SA (ADCT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript | Seeking Alpha | 2026-01-15 16:15:59 |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT | NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC Therapeutics" or the "Company") (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. | PRNewsWire | 2026-01-15 10:00:00 |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT | NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC Therapeutics” or the “Company”) (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. | GlobeNewsWire | 2026-01-13 16:58:00 |
| Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year? | Here is how ADC Therapeutics SA (ADCT) and Agenus (AGEN) have performed compared to their sector so far this year. | Zacks Investment Research | 2026-01-13 10:41:38 |
| ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates | Preliminary unaudited fourth quarter and full year 2025 net product revenue of approximately $22M and $73M respectively; cash and cash equivalents of approximately $261M as of December 31, 2025, provide expected cash runway at least to 2028 Anticipated near-term catalysts include LOTIS-7 complete enrollment in first half of 2026 and LOTIS-5 Phase 3 topline data in second quarter 2026 Additional anticipated catalysts include full LOTIS-5 and LOTIS-7 results by end of 2026, with potential compendia inclusions in first half of 2027 and LOTIS-5 regulatory approvals to follow LAUSANNE, Switzerland, Jan. 8, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today provided corporate updates and highlights from its ZYNLONTA® clinical program. "During 2025, we delivered meaningful progress across our ZYNLONTA clinical program and extended our expected cash runway at least to 2028," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. | PRNewsWire | 2026-01-08 16:05:00 |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT | NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC Therapeutics" or the "Company") (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. | PRNewsWire | 2026-01-08 10:00:00 |
| ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference | LAUSANNE, Switzerland, Jan. 8, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that Ameet Mallik, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Thursday, January 15, 2026, at 10:30 a.m. | PRNewsWire | 2026-01-08 07:15:00 |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT | NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC Therapeutics” or the “Company”) (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. | GlobeNewsWire | 2026-01-06 11:56:00 |
| ADC Therapeutics Announces New Employee Inducement Grant | LAUSANNE, Switzerland, Jan. 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made a grant of options to purchase an aggregate of 6,000 of the Company's common shares to a new employee on January 2, 2026 ("Grant"). The Grant was offered as material inducement to the employee's employment. | PRNewsWire | 2026-01-02 16:05:00 |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT | NEW YORK, Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC Therapeutics" or the "Company") (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. | PRNewsWire | 2026-01-01 10:00:00 |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT | NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC Therapeutics” or the “Company”) (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. | GlobeNewsWire | 2025-12-30 12:50:00 |
| ADC Therapeutics (ADCT) Upgraded to Buy: Here's Why | ADC Therapeutics (ADCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. | Zacks Investment Research | 2025-12-29 13:00:58 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 8-K | 2026-02-23 | 2026-02-23 | View Filing |
| 4 | 2026-02-18 | 2026-02-18 | View Filing |
| 4 | 2026-02-18 | 2026-02-18 | View Filing |
| 4 | 2026-02-18 | 2026-02-18 | View Filing |
| 4 | 2026-02-18 | 2026-02-18 | View Filing |
| 4 | 2026-02-18 | 2026-02-18 | View Filing |
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G/A | 2026-02-13 | 2026-02-13 | View Filing |
| 8-K | 2026-01-12 | 2026-01-12 | View Filing |
| 8-K | 2026-01-08 | 2026-01-08 | View Filing |
| EFFECT | 2025-12-12 | 2025-12-15 | View Filing |
| 424B3 | 2025-12-12 | 2025-12-12 | View Filing |
| 4 | 2025-12-09 | 2025-12-09 | View Filing |
| 4 | 2025-12-09 | 2025-12-09 | View Filing |
| 4 | 2025-12-09 | 2025-12-09 | View Filing |
| 4 | 2025-12-09 | 2025-12-09 | View Filing |
| 4 | 2025-12-09 | 2025-12-09 | View Filing |
| S-3/A | 2025-12-09 | 2025-12-09 | View Filing |
| 8-K | 2025-12-05 | 2025-12-05 | View Filing |
| SC 13G/A | 2025-11-13 | 2025-11-13 | View Filing |
| S-3 | 2025-11-10 | 2025-11-10 | View Filing |
| 10-Q | 2025-11-10 | 2025-11-10 | View Filing |
| 8-K | 2025-11-10 | 2025-11-10 | View Filing |
| SC 13G/A | 2025-11-05 | 2025-11-05 | View Filing |
| 4 | 2025-10-28 | 2025-10-28 | View Filing |
| 8-K | 2025-10-14 | 2025-10-14 | View Filing |
| S-8 | 2025-09-30 | 2025-09-30 | View Filing |
| 8-K | 2025-09-30 | 2025-09-30 | View Filing |
| SC 13G/A | 2025-08-14 | 2025-08-14 | View Filing |
| S-8 | 2025-08-12 | 2025-08-12 | View Filing |
| 10-Q | 2025-08-12 | 2025-08-12 | View Filing |
| 8-K | 2025-08-12 | 2025-08-12 | View Filing |
| 424B3 | 2025-07-10 | 2025-07-10 | View Filing |
| EFFECT | 2025-07-10 | 2025-07-10 | View Filing |
| S-3 | 2025-06-30 | 2025-06-30 | View Filing |
| SC 13G | 2025-06-17 | 2025-06-17 | View Filing |
| 4 | 2025-06-17 | 2025-06-17 | View Filing |
| 4 | 2025-06-17 | 2025-06-17 | View Filing |
| 4 | 2025-06-17 | 2025-06-17 | View Filing |
| 4 | 2025-06-17 | 2025-06-17 | View Filing |
| 4 | 2025-06-17 | 2025-06-17 | View Filing |
| 4 | 2025-06-17 | 2025-06-17 | View Filing |
| 4 | 2025-06-13 | 2025-06-13 | View Filing |
| 8-K | 2025-06-12 | 2025-06-12 | View Filing |
| 4 | 2025-06-05 | 2025-06-05 | View Filing |
| 4 | 2025-06-05 | 2025-06-05 | View Filing |
| 4 | 2025-06-05 | 2025-06-05 | View Filing |
| 4 | 2025-06-05 | 2025-06-05 | View Filing |
| 4 | 2025-06-05 | 2025-06-05 | View Filing |
| 4 | 2025-06-05 | 2025-06-05 | View Filing |
| 4 | 2025-06-05 | 2025-06-05 | View Filing |
| 3 | 2025-06-05 | 2025-06-05 | View Filing |
| 3/A | 2025-06-05 | 2025-06-05 | View Filing |
| 8-K | 2025-06-05 | 2025-06-05 | View Filing |
| SC 13G/A | 2025-05-19 | 2025-05-19 | View Filing |
| 4 | 2025-05-19 | 2025-05-19 | View Filing |
| 4 | 2025-05-19 | 2025-05-19 | View Filing |
| 10-Q | 2025-05-14 | 2025-05-14 | View Filing |
| 8-K | 2025-05-14 | 2025-05-14 | View Filing |
| 4 | 2025-05-08 | 2025-05-08 | View Filing |
| SC 13G/A | 2025-04-24 | 2025-04-24 | View Filing |
| DEF 14A | 2025-04-21 | 2025-04-21 | View Filing |
| DEFA14A | 2025-04-21 | 2025-04-21 | View Filing |
| PRE 14A | 2025-04-09 | 2025-04-09 | View Filing |
| ARS | 2025-03-27 | 2025-03-27 | View Filing |
| 10-K | 2025-03-27 | 2025-03-27 | View Filing |
| 8-K | 2025-03-27 | 2025-03-27 | View Filing |
| 4 | 2025-02-14 | 2025-02-14 | View Filing |
| 4 | 2025-02-14 | 2025-02-14 | View Filing |
| 4 | 2025-02-14 | 2025-02-14 | View Filing |
| 4 | 2025-02-14 | 2025-02-14 | View Filing |
| 4 | 2025-02-14 | 2025-02-14 | View Filing |
| SC 13G | 2025-02-14 | 2025-02-14 | View Filing |
| SC 13G | 2025-02-03 | 2025-02-03 | View Filing |
| 8-K | 2025-01-13 | 2025-01-13 | View Filing |
| 4 | 2024-12-13 | 2024-12-13 | View Filing |
| 4 | 2024-12-09 | 2024-12-09 | View Filing |
| 4 | 2024-12-09 | 2024-12-09 | View Filing |
| 4 | 2024-12-09 | 2024-12-09 | View Filing |
| 4 | 2024-12-09 | 2024-12-09 | View Filing |
| 4 | 2024-12-09 | 2024-12-09 | View Filing |
| 4 | 2024-12-06 | 2024-12-06 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| 8-K | 2024-11-13 | 2024-11-13 | View Filing |
| SC 13G/A | 2024-11-13 | 2024-11-13 | View Filing |
| SC 13G/A | 2024-11-13 | 2024-11-13 | View Filing |
| 10-Q | 2024-11-07 | 2024-11-07 | View Filing |
| 8-K | 2024-11-07 | 2024-11-07 | View Filing |
| DEFA14A | 2024-09-23 | 2024-09-23 | View Filing |
| DEF 14A | 2024-09-23 | 2024-09-23 | View Filing |
| PRE 14A | 2024-09-13 | 2024-09-13 | View Filing |
| EFFECT | 2024-08-14 | 2024-08-14 | View Filing |
| S-3 | 2024-08-06 | 2024-08-06 | View Filing |
| 10-Q | 2024-08-06 | 2024-08-06 | View Filing |
| 8-K | 2024-08-06 | 2024-08-06 | View Filing |
| 4 | 2024-07-03 | 2024-07-03 | View Filing |
| 4 | 2024-06-18 | 2024-06-18 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Quantum Inspired Strategy | 62.78% | 1 | 571 | 0.02 | 0.06 | 63.99 |
| Genetic Strat | 47.78% | 1 | 1077 | 0.02 | 0.03 | 48.99 |
| Guppy Multiple Moving Average Strategy | 46.04% | 1.01 | 572 | 0.02 | 0.05 | 47.25 |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | x | xxxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxx | xxxxxx% | x | xx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xxxx | x | x | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xxxx | x | x | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | x | x | x |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxxx | xxxxx | xx |
| xxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |